K M Schmit1, N Shah2, S Kammerer2, S Bamrah Morris2, S M Marks2. 1. Division of Tuberculosis Elimination, US Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Mailstop US12-4, 1600 Clifton Road, Atlanta, GA, 30329, USA. kmschmit@cdc.gov. 2. Division of Tuberculosis Elimination, US Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Mailstop US12-4, 1600 Clifton Road, Atlanta, GA, 30329, USA.
Abstract
BACKGROUND: Persons living with HIV are more likely to have tuberculosis (TB) disease attributed to recent transmission (RT) and to die during TB treatment than persons without HIV. We examined factors associated with RT or mortality among TB/HIV patients. METHODS: Using National TB Surveillance System data from 2011 to 2016, we calculated multivariable adjusted odds ratios (aOR) with 99% confidence intervals (CI) to estimate associations between patient characteristics and RT or mortality. Mortality analyses were restricted to 2011-2014 to allow sufficient time for reporting outcomes. RESULTS: TB disease was attributed to RT in 491 (20%) of 2415 TB/HIV patients. RT was more likely among those reporting homelessness (aOR, 2.6; CI, 2.0, 3.5) or substance use (aOR,1.6; CI, 1.2, 2.1) and among blacks (aOR,1.8; CI, 1.2, 2.8) and Hispanics (aOR, 1.8; CI, 1.1, 2.9); RT was less likely among non-US-born persons (aOR, 0.2; CI, 0.2, 0.3). The proportion who died during TB treatment was higher among persons with HIV than without (8.6% versus 5.2%; p < 0.0001). Among 2273 TB/HIV patients, 195 died during TB treatment. Age ≥ 65 years (aOR, 5.3; CI, 2.4, 11.6), 45-64 years (aOR, 2.2; CI, 1.4, 3.4), and having another medical risk factor for TB (aOR, 3.3; CI, 1.8, 6.2) were associated with death; directly observed treatment (DOT) for TB was protective (aOR, 0.5; CI, 0.2, 1.0). CONCLUSIONS: Among TB/HIV patients, blacks, Hispanics, and those reporting homelessness or substance use should be prioritized for interventions that decrease TB transmission. Improved adherence to treatment through DOT was associated with decreased mortality, but additional interventions are needed to reduce mortality among older patients and those TB/HIV patients with another medical risk factor for TB.
BACKGROUND:Persons living with HIV are more likely to have tuberculosis (TB) disease attributed to recent transmission (RT) and to die during TB treatment than persons without HIV. We examined factors associated with RT or mortality among TB/HIVpatients. METHODS: Using National TB Surveillance System data from 2011 to 2016, we calculated multivariable adjusted odds ratios (aOR) with 99% confidence intervals (CI) to estimate associations between patient characteristics and RT or mortality. Mortality analyses were restricted to 2011-2014 to allow sufficient time for reporting outcomes. RESULTS:TB disease was attributed to RT in 491 (20%) of 2415 TB/HIVpatients. RT was more likely among those reporting homelessness (aOR, 2.6; CI, 2.0, 3.5) or substance use (aOR,1.6; CI, 1.2, 2.1) and among blacks (aOR,1.8; CI, 1.2, 2.8) and Hispanics (aOR, 1.8; CI, 1.1, 2.9); RT was less likely among non-US-born persons (aOR, 0.2; CI, 0.2, 0.3). The proportion who died during TB treatment was higher among persons with HIV than without (8.6% versus 5.2%; p < 0.0001). Among 2273 TB/HIVpatients, 195 died during TB treatment. Age ≥ 65 years (aOR, 5.3; CI, 2.4, 11.6), 45-64 years (aOR, 2.2; CI, 1.4, 3.4), and having another medical risk factor for TB (aOR, 3.3; CI, 1.8, 6.2) were associated with death; directly observed treatment (DOT) for TB was protective (aOR, 0.5; CI, 0.2, 1.0). CONCLUSIONS: Among TB/HIVpatients, blacks, Hispanics, and those reporting homelessness or substance use should be prioritized for interventions that decrease TB transmission. Improved adherence to treatment through DOT was associated with decreased mortality, but additional interventions are needed to reduce mortality among older patients and those TB/HIVpatients with another medical risk factor for TB.
Authors: Suzanne F Beavers; Lisa Pascopella; Amy L Davidow; Joan M Mangan; Yael R Hirsch-Moverman; Jonathan E Golub; Henry M Blumberg; Risa M Webb; Rachel A Royce; Susan E Buskin; Michael K Leonard; Paul C Weinfurter; Robert W Belknap; Stephen E Hughes; Jon V Warkentin; Sharon F Welbel; Thaddeus L Miller; Saini R Kundipati; Michael Lauzardo; Pennan M Barry; Dolly J Katz; Denise O Garrett; Edward A Graviss; Jennifer M Flood Journal: Ann Am Thorac Soc Date: 2018-06
Authors: G Chamie; A Luetkemeyer; M Walusimbi-Nanteza; A Okwera; C C Whalen; R D Mugerwa; D V Havlir; E D Charlebois Journal: Int J Tuberc Lung Dis Date: 2010-10 Impact factor: 2.373
Authors: Rachel Albalak; Richard J O'Brien; J Steve Kammerer; Sean M O'Brien; Suzanne M Marks; Kenneth G Castro; Marisa Moore Journal: Arch Intern Med Date: 2007-12-10
Authors: Payam Nahid; Leah G Jarlsberg; Irina Rudoy; Bouke C de Jong; Alon Unger; L Masae Kawamura; Dennis H Osmond; Philip C Hopewell; Charles L Daley Journal: BMC Infect Dis Date: 2011-01-03 Impact factor: 3.090
Authors: Peter F Rebeiro; Stephen J Gange; Michael A Horberg; Alison G Abraham; Sonia Napravnik; Hasina Samji; Baligh R Yehia; Keri N Althoff; Richard D Moore; Mari M Kitahata; Timothy R Sterling; Frank C Curriero Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240
Authors: Maria De Lourdes García-García; Alfredo Ponce-De-León; Maria Cecilia García-Sancho; Leticia Ferreyra-Reyes; Manuel Palacios-Martínez; Javier Fuentes; Midori Kato-Maeda; Miriam Bobadilla; Peter Small; José Sifuentes-Osornio Journal: Emerg Infect Dis Date: 2002-11 Impact factor: 6.883